Literature DB >> 12738668

Drug-induced thrombocytopenia: localization of the binding site of GPIX-specific quinine-dependent antibodies.

Parisa Asvadi1, Zohra Ahmadi, Beng H Chong.   

Abstract

Immune thrombocytopenia is a common complication of therapy with a large number of drugs. The most widely studied drug-induced immune thrombocytopenia (DIT) is caused by quinine. In most cases of DIT, antibodies bind to the platelet membrane glycoprotein (GP) Ib-IX complex in a drug-dependent fashion and bring about increased platelet clearance by the reticuloendothelial system resulting in thrombocytopenia. Here, we report the characterization of the quinine-dependent antibody activity of sera from 13 patients with quinine-induced thrombocytopenia. In our series of patients, GPIX was the most prevalent target of quinine-dependent antibodies. To identify the structural determinants of GPIX recognized by quinine-dependent antibodies, 4 chimeric mouse/human GPIX constructs and stable Chinese hamster ovary (CHO) cell lines that expressed the chimeras in association with GPIbalpha and GPIbbeta were produced. The analysis of 6 patient sera with the chimeric cell lines provided evidence for localization of the anti-GPIX quinine-dependent antibody binding site to the C-ext region (amino acid [aa] 64-135) of human GPIX. Further characterization of the C-ext region of the GPIX indicated that replacement of the Arg110 and Gln115 of the human GPIX with the corresponding residues from mouse (Gln and Glu, respectively) resulted in a significant reduction in the binding of GPIX antibodies in our series of patients, with Arg110Gln, giving a more pronounced effect than Gln115Glu. Hence, these 2 residues, particularly Arg110, play an important role in the structure of the antigenic site on GPIX recognized by anti-GPIX antibodies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12738668     DOI: 10.1182/blood-2002-07-2175

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  A hypothesis that explains the heterogeneity of drug-induced immune thrombocytopenia.

Authors:  Renhao Li
Journal:  Blood       Date:  2010-01-28       Impact factor: 22.113

2.  Expanding the binding model of DITP.

Authors:  Renhao Li
Journal:  Blood       Date:  2015-10-29       Impact factor: 22.113

3.  Fine specificity of drug-dependent antibodies reactive with a restricted domain of platelet GPIIIA.

Authors:  Julie A Peterson; Tamara N Nelson; Adam J Kanack; Richard H Aster
Journal:  Blood       Date:  2007-10-24       Impact factor: 22.113

4.  Quinine-induced severe thrombocytopenia: the importance of taking a detailed drug history.

Authors:  Muhajir Mohamed; Robert Hayes
Journal:  BMJ Case Rep       Date:  2013-10-03

5.  Mechanism of quinine-dependent monoclonal antibody binding to platelet glycoprotein IIb/IIIa.

Authors:  Daniel W Bougie; Julie Peterson; Mark Rasmussen; Richard H Aster
Journal:  Blood       Date:  2015-09-09       Impact factor: 22.113

6.  Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of αIIb/β3 integrin.

Authors:  Daniel W Bougie; Mark Rasmussen; Jieqing Zhu; Richard H Aster
Journal:  Blood       Date:  2012-04-06       Impact factor: 22.113

Review 7.  Drug-induced thrombocytopenia.

Authors:  Gian Paolo Visentin; Chao Yan Liu
Journal:  Hematol Oncol Clin North Am       Date:  2007-08       Impact factor: 3.722

Review 8.  Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management.

Authors:  R H Aster; B R Curtis; J G McFarland; D W Bougie
Journal:  J Thromb Haemost       Date:  2009-04-02       Impact factor: 5.824

9.  Quinine-dependent, platelet-reactive monoclonals mimic antibodies found in patients with quinine-induced immune thrombocytopenia.

Authors:  Daniel W Bougie; Jessica Birenbaum; Mark Rasmussen; Mortimer Poncz; Richard H Aster
Journal:  Blood       Date:  2008-10-23       Impact factor: 22.113

Review 10.  Pathobiology of secondary immune thrombocytopenia.

Authors:  Douglas B Cines; Howard Liebman; Roberto Stasi
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.